Ignite Creation Date:
2025-12-24 @ 4:49 PM
Ignite Modification Date:
2025-12-29 @ 12:25 AM
Study NCT ID:
NCT01577550
Status:
COMPLETED
Last Update Posted:
2016-11-16
First Post:
2012-04-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
Sponsor:
AbbVie
Organization:
Study Overview
Official Title:
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2012-000081-37 | EUDRACT_NUMBER | EudraCT | View |